Document is current

Article History

Received: 9 October 2017

Accepted: 31 October 2018

First Online: 19 November 2018

Authors’ information

: Not applicable.

: The study was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki and was approved by independent ethics committees at participating sites. Patients (or parents/guardians) provided written, informed consent prior to enrollment.

: Not applicable.

: ATT reports receiving research funding and honoraria from Novartis and research funding from Celgene Corporations; RO reports receiving honoraria from Novartis and Apopharma, and for being part of the Italian advisory board for BlueBird Bio; SP reports receiving research funding and honoraria from Novartis and research funding from Acceleron; AKo reports receiving honoraria from Novartis, Amgen, and Janssen, and consultancy for Gilead, Roche, and Celgene; AKa reports receiving research funding from Novartis and participating in advisory boards and educational forums sponsored from Novartis, Apopharma, and Celgene; JBP reports consultancy, receiving research grant funding and honoraria from Novartis Pharmaceuticals, consultancy and honoraria from Shire, and consultancy for Celgene. JBP is supported by the NIHR University College London Hospitals Biomedical Research Centre; VH, AZ, and RMH were full-time employees of Novartis at the time of these analyses; GBR and A-SG declares that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.